Clinical trial
Combination Chemotherapy in Treating Children With Very High Risk Acute…
NCT00003783 · Children's Oncology Group, Other · Completed
Key facts
| NCT number | NCT00003783 |
|---|---|
| Title | Combination Chemotherapy in Treating Children With Very High Risk Acute Lymphocytic Leukemia |
| Official title | ALinC 17: Continuous Intensification for Very High Risk Acute Lymphocytic Leukemia (A.L.L.): A Pediatric Oncology Group Pilot Study |
| Lead sponsor | Children's Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Biological, Drug, Radiation |
| Interventions | filgrastim, asparaginase, cyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone, etoposide, idarubicin, leucovorin calcium, mercaptopurine and 4 more |
| Enrollment | 36 |
| Start date | Mar 1, 1999 |
| Primary completion | Nov 1, 2002 |
| Completion | Mar 1, 2007 |
| First posted | Apr 27, 2004 |
| Last update posted | Jul 28, 2014 |
| Countries | Canada, Netherlands, Puerto Rico, Switzerland, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: